Suppr超能文献

肝类器官研究的十年进展:疾病建模的新突破

A decade of liver organoids: Advances in disease modeling.

机构信息

Guangzhou Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou, Guangdong, China.

Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.

出版信息

Clin Mol Hepatol. 2023 Jul;29(3):643-669. doi: 10.3350/cmh.2022.0428. Epub 2023 Mar 6.

Abstract

Liver organoids are three-dimensional cellular tissue models in which cells interact to form unique structures in culture. During the past 10 years, liver organoids with various cellular compositions, structural features, and functional properties have been described. Methods to create these advanced human cell models range from simple tissue culture techniques to complex bioengineering approaches. Liver organoid culture platforms have been used in various research fields, from modeling liver diseases to regenerative therapy. This review discusses how liver organoids are used to model disease, including hereditary liver diseases, primary liver cancer, viral hepatitis, and nonalcoholic fatty liver disease. Specifically, we focus on studies that used either of two widely adopted approaches: differentiation from pluripotent stem cells or epithelial organoids cultured from patient tissues. These approaches have enabled the generation of advanced human liver models and, more importantly, the establishment of patient-tailored models for evaluating disease phenotypes and therapeutic responses at the individual level.

摘要

肝类器官是一种三维细胞组织模型,其中细胞相互作用,在培养中形成独特的结构。在过去的 10 年中,已经描述了具有各种细胞组成、结构特征和功能特性的肝类器官。创建这些先进的人类细胞模型的方法从简单的组织培养技术到复杂的生物工程方法不等。肝类器官培养平台已被用于各种研究领域,从模拟肝脏疾病到再生治疗。本综述讨论了肝类器官如何用于模拟疾病,包括遗传性肝脏疾病、原发性肝癌、病毒性肝炎和非酒精性脂肪性肝病。具体来说,我们专注于使用两种广泛采用的方法之一的研究:多能干细胞的分化或从患者组织培养的上皮类器官。这些方法使先进的人类肝脏模型的产生成为可能,更重要的是,为在个体水平上评估疾病表型和治疗反应建立了基于患者的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/9149859cd8a4/cmh-2022-0428f1.jpg

相似文献

1
A decade of liver organoids: Advances in disease modeling.
Clin Mol Hepatol. 2023 Jul;29(3):643-669. doi: 10.3350/cmh.2022.0428. Epub 2023 Mar 6.
2
Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.
J Hepatol. 2019 Nov;71(5):970-985. doi: 10.1016/j.jhep.2019.06.030. Epub 2019 Jul 9.
3
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease.
Gastroenterology. 2020 Oct;159(4):1471-1486.e12. doi: 10.1053/j.gastro.2020.06.010. Epub 2020 Jun 15.
4
Organoids of liver diseases: From bench to bedside.
World J Gastroenterol. 2019 Apr 28;25(16):1913-1927. doi: 10.3748/wjg.v25.i16.1913.
5
Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids.
Front Cell Dev Biol. 2021 Oct 1;9:748576. doi: 10.3389/fcell.2021.748576. eCollection 2021.
6
Advances in development and application of human organoids.
3 Biotech. 2021 Jun;11(6):257. doi: 10.1007/s13205-021-02815-7. Epub 2021 May 8.
8
Hepatitis B virus infection modeling using multi-cellular organoids derived from human induced pluripotent stem cells.
World J Gastroenterol. 2021 Aug 7;27(29):4784-4801. doi: 10.3748/wjg.v27.i29.4784.
9
Bioengineering tissue morphogenesis and function in human neural organoids.
Semin Cell Dev Biol. 2021 Mar;111:52-59. doi: 10.1016/j.semcdb.2020.05.025. Epub 2020 Jun 12.
10
Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.
Int J Mol Sci. 2018 Mar 21;19(4):936. doi: 10.3390/ijms19040936.

引用本文的文献

1
"Armed retina"-generating microglial retinal organoids, where are we now?
Front Cell Dev Biol. 2025 May 30;13:1574283. doi: 10.3389/fcell.2025.1574283. eCollection 2025.
2
Modeling hepatic steatosis with human adult stem cell-derived liver organoids.
iScience. 2025 Apr 3;28(5):112344. doi: 10.1016/j.isci.2025.112344. eCollection 2025 May 16.
3
Computational and experimental advances in liver-on-a-chip technology for cancer research: a systematic review.
Biophys Rev. 2024 Dec 14;17(1):151-167. doi: 10.1007/s12551-024-01260-z. eCollection 2025 Feb.
4
Farnesoid X receptor: a potential key target for maintaining liver organoid growth.
Biomater Transl. 2024 Nov 15;5(4):454-456. doi: 10.12336/biomatertransl.2024.04.011. eCollection 2024.
5
Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects.
Curr Issues Mol Biol. 2024 Dec 26;47(1):7. doi: 10.3390/cimb47010007.
6
Liver organoids: Current advances and future applications for hepatology.
Clin Mol Hepatol. 2025 Feb;31(Suppl):S327-S348. doi: 10.3350/cmh.2024.1040. Epub 2024 Dec 26.
7
Ex Vivo Tools and Models in MASLD Research.
Cells. 2024 Nov 5;13(22):1827. doi: 10.3390/cells13221827.
8
Generation of -like multicellular liver organoids by mimicking developmental processes: A review.
Regen Ther. 2024 Jun 8;26:219-234. doi: 10.1016/j.reth.2024.05.020. eCollection 2024 Jun.
9
Generation and characterization of mature hepatocyte organoids for liver metabolic studies.
J Cell Sci. 2024 May 15;137(10). doi: 10.1242/jcs.261961. Epub 2024 May 28.

本文引用的文献

1
Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update.
Int J Mol Sci. 2022 Oct 16;23(20):12376. doi: 10.3390/ijms232012376.
2
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.
Cell. 2022 Oct 27;185(22):4216-4232.e16. doi: 10.1016/j.cell.2022.09.031. Epub 2022 Oct 13.
3
Advancements in MAFLD Modeling with Human Cell and Organoid Models.
Int J Mol Sci. 2022 Oct 6;23(19):11850. doi: 10.3390/ijms231911850.
4
SARS-CoV-2 infection of human pluripotent stem cell-derived liver organoids reveals potential mechanisms of liver pathology.
iScience. 2022 Oct 21;25(10):105146. doi: 10.1016/j.isci.2022.105146. Epub 2022 Sep 16.
5
Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Liver Int. 2023 Aug;43 Suppl 1:80-86. doi: 10.1111/liv.15389. Epub 2022 Aug 23.
7
Mechanisms of ductular reaction in non-alcoholic steatohepatitis.
World J Gastroenterol. 2022 May 21;28(19):2088-2099. doi: 10.3748/wjg.v28.i19.2088.
8
Breakthroughs in hepatitis C research: from discovery to cure.
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. doi: 10.1038/s41575-022-00608-8. Epub 2022 May 20.
9
EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
Sci Rep. 2022 May 14;12(1):8007. doi: 10.1038/s41598-022-12076-w.
10
Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
Gut. 2023 Jan;72(1):216-218. doi: 10.1136/gutjnl-2021-326617. Epub 2022 Apr 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验